Literature DB >> 8621765

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

J Wilborn1, M Bailie, M Coffey, M Burdick, R Strieter, M Peters-Golden.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disorder characterized by inflammation, fibroblast proliferation, and accumulation of extracellular matrix proteins. Leukotrienes (LTs) are pro-inflammatory and pro-fibrogenic mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. They are thought to play a role in a number of disease processes, but have received relatively little attention in investigations into the pathogenesis of IPF. In this study, we measured the levels of immunoreactive LTs B(4) and C(4) in homogenates of lung tissue obtained from patients with newly diagnosed, untreated IPF, as compared to levels measured in homogenates of uninvolved nonfibrotic lung tissue from patients undergoing resectional surgery for bronchogenic carcinoma. Compared to homogenates on nonfibrotic control lung, homogenates from IPF patients contained 15-fold more LTB(4) and 5-fold more LTC(4). IPF homogenate levels of LTB(4) were significantly correlated with histologic indices of both inflammation (r=0.861) and fibrosis (r=0.926). Activation of 5-LO is known from in vitro studies to be associated with localization of the enzyme at the nuclear membrane. Immunohistochemical staining for 5-LO protein in alveolar macrophages (AMs) demonstrated that such an "activated" localization pattern was significantly more frequent in IPF lung (19.2+/-3.3% of cells) than in control lung (9.3+/-0.9%); this localization pattern was rarely seen (3.2%) in sections from a truly normal transplant donor lung. Consistent with these data, AMs obtained from IPF patients by bronchoalveolar lavage, purified by adherence, and cultured in the absence of a stimulus for 16 h elaborated significantly greater amounts of LTB(4) and LTC(4) than did control AMs obtained from normal volunteers. These data indicate that the 5-LO pathway is constitutively activated in the lungs of patients with IPF, and the AM represents at least one cellular source of LT overproduction in this disorder. We speculate that LTs participate in the pathogenesis of IPF, and their overproduction in this disorder may be amenable to specific pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621765      PMCID: PMC507250          DOI: 10.1172/JCI118612

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  The diagnosis of asbestosis.

Authors:  R N Jones
Journal:  Am Rev Respir Dis       Date:  1991-09

2.  Alterations in the pattern of arachidonate metabolism accompany rat macrophage differentiation in the lung.

Authors:  M Peters-Golden; R W McNish; R Hyzy; C Shelly; G B Toews
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

Review 3.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases.

Authors:  R A Lewis; K F Austen; R J Soberman
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

4.  The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat.

Authors:  J E Vincent; M A Vermeer; W J Kort; F J Zijlstra
Journal:  Biochim Biophys Acta       Date:  1990-02-06

5.  A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma.

Authors:  M L Cloud; G C Enas; J Kemp; T Platts-Mills; L C Altman; R Townley; D Tinkelman; T King; E Middleton; A L Sheffer
Journal:  Am Rev Respir Dis       Date:  1989-11

6.  Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation.

Authors:  M Peters-Golden; R W McNish
Journal:  Biochem Biophys Res Commun       Date:  1993-10-15       Impact factor: 3.575

7.  Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome.

Authors:  G R Bernard; V Korley; P Chee; B Swindell; A W Ford-Hutchinson; P Tagari
Journal:  Am Rev Respir Dis       Date:  1991-08

8.  Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis.

Authors:  N Khalil; R N O'Connor; H W Unruh; P W Warren; K C Flanders; A Kemp; O H Bereznay; A H Greenberg
Journal:  Am J Respir Cell Mol Biol       Date:  1991-08       Impact factor: 6.914

9.  Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages.

Authors:  T G Brock; R W McNish; M Peters-Golden
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

10.  Identification and isolation of a membrane protein necessary for leukotriene production.

Authors:  D K Miller; J W Gillard; P J Vickers; S Sadowski; C Léveillé; J A Mancini; P Charleson; R A Dixon; A W Ford-Hutchinson; R Fortin
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

View more
  47 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Disorders of lung matrix remodeling.

Authors:  Harold A Chapman
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 3.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

5.  gamma-Linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters.

Authors:  V A Ziboh; M Yun; D M Hyde; S N Giri
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

6.  TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis.

Authors:  Stephen K Frankel; Gregory P Cosgrove; Seung-Ick Cha; Carlyne D Cool; Murry W Wynes; Benjamin L Edelman; Kevin K Brown; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-04       Impact factor: 6.914

Review 7.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

Review 8.  Paracrine functions of fibrocytes to promote lung fibrosis.

Authors:  Kathryn R Kleaveland; Bethany B Moore; Kevin K Kim
Journal:  Expert Rev Respir Med       Date:  2014-01-22       Impact factor: 3.772

9.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

10.  Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.

Authors:  Thomas C Beller; Daniel S Friend; Akiko Maekawa; Bing K Lam; K Frank Austen; Yoshihide Kanaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.